|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 美国临床肿瘤学会IV期非小细胞肺癌化疗的临床实践指南更新显示文摘本文旨在为IV期非小细胞肺癌患者的治疗提供更新版推荐。本文资料检索源自2002年以来公布的相关随机试验文献。此指南范围限于化疗与生物治疗。更新委员会对这些文献进行了总结并提供了推荐更新。162篇文献符合标准被纳入参考。本推荐基于可改善总生存期的治疗方法。仅改善无进展生存期的治疗方法推动了对毒性及生存质量的监测。对于体力状态评分为0分或1分患者的一线治疗,可推荐以铂类为基础的细胞毒性药物的两药联用。对铂类治疗有禁忌的患者,可采用非铂类细胞毒性两药联合。对于体力状态评分为2分的患者,单一细胞毒性药物即可。对于疾病进展或经过4个周期的治疗仍对治疗无反应的患者,应停止一线细胞毒性化疗。即使在6个周期后患者对治疗仍有反应,亦应停止两药细胞毒性化疗。对于伴有明确的表皮生长因子受体(epidermal growth factor receptor,EGFR)突变的患者,可推荐一线采用吉非替尼治疗;对于EGFR突变为阴性或不明确的患者,细胞毒性化疗更佳。除具有特定临床特征的患者外,可推荐贝伐单抗与卡铂-紫杉醇联用。对于通过免疫组化证实EGFR阳性的肿瘤患者,可推荐西妥昔单抗与顺铂-长春瑞滨联用。多西紫杉醇、厄洛替尼、吉非替尼或培美曲塞被推荐作为二线治疗。对于未曾接受过厄洛替尼或吉非替尼治疗的患者,可推荐厄洛替尼作为三线治疗。现有数据不足以推荐常规三线采用细胞毒性药物。已有的证据也不足以推荐常规应用分子标记物选择化疗。 | Christopher G. AZZOLI Sherman Baker JR Sarah TEMIN William PAO Timothy ALIFF Julie BRAHMER David H. JOHNSON Janessa L. LASKIN Gregory MASTERS Daniel MILTON Luke NORDQUIST David G. PFISTER Steven PIANTADOSI Joan H. SCHILLER Reily SMITH Thomas J. SMITH John R. STRAWN David TRENT Giuseppe GIACCONE 丁燕(翻译) 南娟(翻译) 刘谦(翻译) 周清华(校对) 陈军(校对) | 2010 | 中国肺癌杂志2010，13，3： | 43 |
| 2 | In vivo toxicity screening programs using metabonomics显示文摘 | Robosky LC Robertson DG Baker DJ Rane S Reily MD | 2002 | Comb Chem High Throughput Screen2002，5，8： | 2 |
| 3 | Improvement in oxygenation by phenylephrine and nitric oxide in patients with adult respiratory distress syndrome 显示文摘 | Doering E B Hanson C W Reily D J | 1997 | Anesthesiology1997，87，： | 2 |
| 4 | Second-generation epidermal growth factor receptor tyro- sine ldnase inhibitors in nonsmall-cell lung cancer 显示文摘 | Reily GJ | 2008 | J Thorac On- col2008，3，： | 1 |
| 5 | Metabonomic assessment of vasculitis in rats显示文摘 | Robertson DG Reily MD Albassam M | 2001 | Cardiovasc Toxicol2001，1，1： | 1 |
| 6 | Plasminogen activator inhibitor - 1 suppresses endogenous fibrinolysis in a caninemodel of pulmonary embolism 显示文摘 | Reily CF Fujita T Hutzelmann JE etal | 1991 | Circulation1991，84，1： | 1 |
| 7 | Advances in mass spectrometry applied to pharmaceutical metabolomics 显示文摘 | DREXLER D M REILY M D SHIPKOVA P A | 2011 | Anal Bioanal Chem2011，399，8： | 1 |
| 8 | Endotoxin, sepsis, and the primrose path显示文摘 | Reily M Newcomb D E Remick D | 1999 | Shock1999，12，6： | 1 |
| 9 | Metabonomics : evaluation of nuclear magneticresonance (NMR) and pattern recognition technology for rapid in vivo screening of liverand kidney toxicants显示文摘 | Robertson DG Reily MD Sigler RE | 2000 | Tox icol Sci2000，57，2： | 1 |
| 10 | Angiostatin: a novel anglogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma显示文摘 | O' Reily MS Holmgren L Shing Y | 1994 | Cell1994，79，： | 1 |
| 11 | Supraspinatous tears:propagation and strain alteration显示文摘 | Reily P Amis AS Wallace AL | | 0，，： | 1 |
| 12 | Efficient design of oversampled NPR GDFT filter banks显示文摘 | M R Wilbur T N Davidson J P Reily | 2004 | IEEE Trans Signal Processing2004，52，： | 1 |
| 13 | Cellular Signaling and Production of Galactose-Deficient IgAl in IgA Nephropathy, an Autoimmune Disease显示文摘 | Reily C Ueda H Huang ZQ | 2014 | Journal of Immunology Research2014，20，4： | 1 |
| 14 | Antimierobial activity of the major components of the essential oil of Melaleuca alternifolia 显示文摘 | Carson C F' Reily T V | 1995 | J Appl Bacteriology1995，78，3： | 1 |
| 15 | Graft loss following liver transplantation in patients with chronic hepatitis C显示文摘 | Rosen HR O'Reily PM Shackleton CR | 1996 | Transplantation1996，62，12： | 1 |
| 16 | KRAS mutation and primary resistance of lung adenocarcinomas to gefitinid and erlitinib显示文摘 | Pao W Wang T Y Reily G D | 2005 | PLOS Medicine2005，2，： | 1 |
| 17 | The role of sentinel lymph node mapping in staging of colon and rectal cancer显示文摘 | Esser S Reilly WT Reily LB | 2001 | Dis Colon Rectum2001，44，： | 1 |
| 18 | K-RAS mutations and primary resistance of lung adenocarcinomas to gefitinib and erlotinib显示文摘 | PAO W WANG TY REILY G J | 2005 | PLoS Medicine2005，2，： | 1 |
| 19 | Metabonomics: evaluation of nuclear magnetic resonance (NMR) and pattern recognition technology for rapid in vivo screening of liver and kidney toxicants显示文摘 | Robertson DG Reily MD Sigler RE | 2000 | Toxicol Sci2000，57，2： | 1 |
| 20 | The CEO,the board of directors and executive compensation:economic and psychological perspectives显示文摘 | Main G C O'Reily J Wade | 1995 | Industrial and Corporate Change1995，，11： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员